Oncology PKPDADC

Charged trastuzumab ADC plasma disposition

Reference paper ↗

A reduced plasma PK model representing first-order elimination, concentration, half-life, and cumulative exposure of a positively charged trastuzumab-vc-MMAE ADC.

Therapeutic
Positively charged trastuzumab-vc-MMAE ADC, trastuzumab
Modality
Antibody–drug conjugate (ADC)
Target
HER2 / ERBB2
Disease
HER2-positive preclinical tumor models
Model type
PKPD, ADC

Complete model workspace

Checking workspace access…

Parameters
1
States
3
Equations
3
Derived outputs
6

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Starting configuration

Charged trastuzumab ADC plasma disposition

Charged trastuzumab ADC plasma disposition

Explore how the starting plasma concentration and first-order elimination rate determine charged trastuzumab ADC concentration, half-life, and cumulative plasma exposure.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–168 hour; step 1

InputDefaultAvailable range
Elimination rate constant0.01609 1/h0.008045–0.02413 1/h

Expected readouts

Drug concentration (nM) · Exposure (AUC) (h*nM) · ADC half-life

Adjustable model parameters

This public explorer exposes 1 curated parameters. Sign in to edit all 1 declared model parameters.

How the model represents the biology

A reduced plasma PK model representing first-order elimination, concentration, half-life, and cumulative exposure of a positively charged trastuzumab-vc-MMAE ADC.

How do initial charged-ADC concentration and elimination set plasma exposure?A scenario initializes charged trastuzumab ADC plasma concentration. The concentration declines by first-order elimination while its integral accumulates as plasma exposure.BIOLOGY OVERVIEWHow do initial charged-ADC concentration and elimination set plasma exposure?Initial plasma ADCScenario-initializedconcentrationFirst-order lossConcentration-proportionaldecayCumulative exposureIntegral of plasmaconcentrationPRIMARY READOUTSPlasma ADC concentrationPlasma ADC concentrationCumulative plasma exposureCumulative plasma exposureModeled half-lifeModeled half-life

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: Administration route, distribution, HER2 binding, payload release, tissue uptake, and tumor effects are outside this one-state decay model.

Modeled relationships (2)
  • Initial plasma ADC → First-order loss: first-order (loss)
  • Initial plasma ADC → Cumulative exposure: integrates C (production)

Modeled relationships: Initial plasma ADC to First-order loss: first-order (loss); Initial plasma ADC to Cumulative exposure: integrates C (production).

Primary readouts: Plasma ADC concentration; Cumulative plasma exposure; Modeled half-life.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID chang_2025_charged_trastuzumab_adc_mice_pkpd.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics